---
title: "EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293078973.md"
description: "EyePoint Pharmaceuticals settled civil claims regarding alleged improper sales and marketing of DEXYCU from 2019 to 2023, paying approximately $4.68 million without admitting liability. The settlement includes a five-year Corporate Integrity Agreement imposing strict compliance and oversight obligations to avoid exclusion from federal healthcare programs. This resolution provides clarity on legacy compliance exposure but may impact near-term cash resources."
datetime: "2026-07-17T21:34:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293078973.md)
  - [en](https://longbridge.com/en/news/293078973.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293078973.md)
generator: "portal-rs"
---

# EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

An update from EyePoint Pharmaceuticals ( (EYPT) ) is now available.

On July 17, 2026, EyePoint, Inc. entered into a settlement agreement with the U.S. Department of Justice, Office of Inspector General of HHS, the Defense Health Agency and a relator to resolve potential civil claims tied to alleged improper sales, marketing, promotional and sampling practices for DEXYCU® from 2019 to 2023, without admitting liability. EyePoint agreed to pay approximately $4.68 million plus interest to federal and state authorities, as well as attorneys’ fees, and secured releases from civil and administrative monetary liability and dismissal of the relator’s action, while a five‑year Corporate Integrity Agreement signed on July 13, 2026 imposes extensive compliance, oversight and training obligations in exchange for avoiding exclusion from Medicare, Medicaid and other federal health care programs, with noncompliance risking penalties or program exclusion.

The settlement requires EyePoint to fund the payments from cash on hand, potentially affecting near‑term cash resources but providing clarity on legacy DEXYCU® compliance exposure. The Corporate Integrity Agreement, including board‑level oversight, independent review, employee screening and formalized policies, positions EyePoint under heightened regulatory scrutiny for five years, shaping its operational practices in federal healthcare markets and signaling to stakeholders a commitment to reinforced compliance structures.

The most recent analyst rating on (EYPT) stock is a Buy  
 with a $40.00 price target.  
 To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock,  
 see the EYPT Stock Forecast page. 

**Spark’s Take on EYPT Stock**

According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.

The score is held down primarily by weak financial performance—collapsing revenue and substantial ongoing cash burn—despite low leverage. Clinical/program momentum and reiterated runway into Q4 2027 provide an offsetting catalyst-driven upside, while technicals are mixed and valuation remains constrained by losses and no dividend.

To see Spark’s full report on EYPT stock,  
 click here. 

**More about EyePoint Pharmaceuticals**

EyePoint, Inc. operates in the pharmaceuticals sector, focusing on ophthalmic treatments and related products. The company previously commercialized DEXYCU®, an intraocular therapy marketed between 2019 and 2023, with sales and promotional activities directed at U.S. healthcare providers and federal health care programs.

**Average Trading Volume:** 1,179,551

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $1.09B

Learn more about EYPT stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)

## Related News & Research

- [EYPT: DURAVYU reduced treatment burden by 42% and maintained strong safety in wet AMD](https://longbridge.com/en/news/296109785.md)
- [EyePoint's eye drug misses main goal in late-stage trial](https://longbridge.com/en/news/296096290.md)
- [13:03 ETEYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals](https://longbridge.com/en/news/296520819.md)
- [These Analysts Slash Their Forecasts On EyePoint](https://longbridge.com/en/news/296252754.md)
- [EyePoint stock craters 71% after drug trial failure. It may be an overreaction.](https://longbridge.com/en/news/296132806.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**